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Abstract
Objective: Though single nucleotide polymorphisms (SNPs) in the non-muscle myosin gene (MYH9) have been reported to
explain most of the excess risk of nondiabetic chronic kidney disease (CKD), in African-Americans, some studies have also
shown associations with diabetic end-stage renal disease. We investigated the association of MYH9 SNPs with renal traits in
a mixed-ancestry South African population prone to diabetes.
Research Design and Methods: Three SNPs known to be associated with CKD (rs4821480, rs5756152 and rs12107) were
genotyped using Taqman assay in 716 adults (198 with diabetes) from the Bellville-South community, Cape Town.
Glomerular filtration rate was estimated (eGFR) and urinary albumin/creatinine ratio (ACR) assessed. Multivariable
regressions were used to relate the SNPs with renal traits.
Results: Mean age was 53.6 years, with the expected differences observed in characteristics by diabetic status. Significant
associations were found between rs575152 and serum creatinine, and eGFR in the total population, and in diabetic
participants (all p#0.003), but not in non-diabetics (all p$0.16), with significant interactions by diabetes status (interaction-
p#0.009). The association with ACR was borderline in diabetic participants (p = 0.05) and non-significant in non-diabetics
(p = 0.85), with significant interaction (interaction p= 0.02). rs12107 was associated with fasting-, 2-hour glucose and HbA1c
in diabetic participants only (interaction-p#0.003), but not with renal traits.
Conclusion: MYH9 SNPs were associated with renal traits only in diabetic participants in this population. Our findings and
other studies suggest that MYH9 may have a broader genetic risk effect on kidney diseases.
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Introduction
The characterization of the associations between chronic kidney
diseases (CKD) and polymorphisms on chromosome 22q12,
namely MYH9 and APOL1 was an immense breakthrough for
population-based genetic studies of CKD [1,2]. The MYH9 gene
encodes for the non-muscle myosin IIA heavy chain, a subunit of
myosin IIA protein [3]. This protein is involved in several
important functions, including cytokinesis, cell motility, mainte-
nance of cell shape and specialized functions such as secretion.
Autosomal-dominant mutations in MYH9 are linked to the
development of the giant platelet syndrome disorders, which in
turn are also associated with susceptibility of progression to renal
failure of glomerular origin [4].
African Americans have been reported to show a dispropor-
tionate risk for specific forms of CKD such as focal segmental
glomerulosclerosis (FSGS) [5], diabetic nephropathy [6], hyper-
tensive nephrosclerosis [7], lupus nephritis [8], and HIV associated
nephropathy (HIVAN) [9]. In 2008 two studies identified single
nucleotide polymorphisms (SNPs) in the MYH9 gene which
conferred most of the increased risk for nondiabetic kidney disease
in African Americans [1,2]. The MYH9 SNPs were clustered into
groups according to linkage disequilibrium blocks: extended or E-1
haplotype (rs4821480, rs2032487, and rs4821481, rs3752462)
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[1,2], S-1 (rs5750248, rs2413396, rs5750250), F-1 (rs16996674,
rs16996677, rs11912763) [10] and L1 (rs12107, rs7078, rs735853,
rs5756129) [11]. Furthermore, some of the SNP’s (rs2032387,
rs1699667, rs821480, rs575152, rs12107) exhibited independent
evidence for association with non-diabetic end-stage renal disease
(ESRD) [11]. Nevertheless, some reports also demonstrated an
association between MYH9 gene polymorphisms and diabetic
ESRD in African-Americans [12,13].
Polymorphisms in the MYH9 gene in relation with kidney
disease have not yet been investigated in mixed ancestry African
populations. Thus, our aim was to explore the association between
MYH9 SNPs and renal traits in the mixed ancestry population of
South Africa which has previously been shown to have a high
prevalence of diabetes [14].
Research Design and Methods
Ethical Considerations
The study was approved by the Cape Peninsula University of
Technology, Faculty of Health and Wellness Sciences ethics
committee (Reference Number: CPUT/HW-REC 2008/002 and
CPUT/HW-REC 2010/H017). The study was conducted ac-
cording to the Code of Ethics of the World Medical Association
(Declaration of Helsinki). All participants signed written informed
consent after all the procedures had been fully explained in the
language of their choice. In addition, permission was also sought
from other relevant authorities such as the city and community
authorities. These authorities granted permission to operate in the
community and also to make use of designated places such as
community halls or nearby schools for data and samples collection.
Study Setting and Population
Participants were members of a cohort study conducted in
Bellville-South, Cape Town, a mixed ancestry Township formed
in the late 1950s. A detailed description of the survey design and
procedures has been previously described [14,15] Briefly, eligible
participants, selected from 1000 households through a multistage
random sampling, were invited to take part in a community based
survey between January 2008 and March 2009, with data
collection through standardized procedures.
Clinical Data
All consenting participants received a standardized interview
and physical examination during which blood pressure was
measured according to World Health Organisation (WHO)
guidelines [16] using a semi-automatic digital blood pressure
monitor (Rossmax PA, USA) on the right arm in sitting position.
Other clinical measurements included the body weight, height,
waist and hip circumferences. Weight (to the nearest 0.1 kg) was
determined with a Sunbeam EB710 digital bathroom scale, which
was calibrated and standardized using a weight of known mass.
Weight measurements were recorded with each subject wearing
light clothing, without shoes and socks. Waist circumference was
measured using a non-elastic tape at the level of the narrowest part
of the torso, as seen from the anterior view. All anthropometric
measurements were performed three times and their average used
for analysis. Participants with no history of doctor diagnosed
diabetes mellitus underwent a 75 g oral glucose tolerance test
(OGTT) as recommended by the WHO [17].
Laboratory Measurements
Blood samples were collected after an overnight fast and
processed for further biochemical analysis. Plasma glucose was
measured by enzymatic hexokinase method (Cobas 6000, Roche
Diagnostics, Germany) and glycated haemoglobin (HbA1c) by
turbidimetric inhibition immunoassay (Cobas 6000, Roche Diag-
nostics, Germany). This method is National Glycohaemoglobin
Standardisation Programme (NGSP) certified according to Roche
Diagnostics. Creatinine measurements were done using the
standardized creatinine assay (Cobas 6000, Roche Diagnostics,
Germany) and urine albumin by the immunoturbidimetric assay
(Cobas 6000, Roche Diagnostics, Germany).
Definitions and Calculations
Diabetes status was based on a history of doctor-diagnosis, a
fasting plasma glucose .=7.26 mmol/l and/or a 2-hour post-
OGTT plasma glucose .11.1 mmol/l. Hypertension was based
on a history of doctor diagnosed hypertension and/or receiving
medications for hypertension or average systolic blood pressure
$140 mmHg and/or average diastolic blood pressure
$90 mmHg. Urinary albumin excretion was quantified in term
of urinary albumin/creatinine ratio (ACR) and participants
ranked according to ACR levels as: normoalbuminuria
(ACR,3.4 mg/mmol), microalbuminuria (3.4#ACR,33.9 mg/
mmol) and macroalbuminuria (ACR$33.9 mg/mmol). Kidney
function was assessed through estimated glomerular filtration rate
(eGFR) for which both the 4-variable Modification of Diet in
Renal Disease (MDRD) equation [18,19] applicable to standard-
ised serum creatinine values, and the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [20] were used,
assuming a black ethnicity for all participants. An eGFR,60 ml/
min was used to defined chronic kidney disease (or CKD stage 3–
5).
SNP Selection and Genotyping
There is no published data on MYH9 SNPs and haplotype
variations in mixed ancestry population from South Africa. We
therefore selected three SNPs that have been shown to exhibit
independent evidence for association with CKD (rs4821480,
rs575152 and rs12107) in prior studies [11]. The SNPs were
genotyped using Taqman genotyping assay (Applied Biosystems,
USA) on a BioRad Optica (Biorad, USA) and confirmed by
sequencing.
Statistical Analysis
Of the 946 participants who took part in the survey, 941
consented for genetic studies. Among the latter, 226 were excluded
for missing data on the genetic or renal trait variables. Therefore,
716 had valid data for the current analyses. General characteristics
of the study group are summarized as count and percentage for
dichotomous traits, mean and standard deviation (SD) or median
and 25th–75th percentiles for quantitative traits. Traits were log-
transformed to approximate normality, where necessary, prior to
analysis. SNPs were tested for departure from Hardy-Weindberg
Equilibrium (HWE) expectation via a chi square goodness of fit
test. Linkage disequilibrium (LD) was estimated using the D’
statistic. Linear regression models were used for the analysis of
quantitative traits and logistic regression models for dichotomous
traits, always assuming additive models for the SNPs. Using linear
and logistic models enabled us to adjust all analyses for known
confounders as specified everywhere in the results. We investigated
the additive allelic association of each SNP with each trait, overall
and according to diabetes status, and tested for heterogeneity by
adding the interaction term of diabetes and each SNP to a model
that contained the main effects of diabetes and the relevant SNP.
Results corresponding to p-values below 5% are described as
significant. We did not adjust for multiple testing. All analyses used
MYH9 Gene and Renal Traits in Diabetes
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the statistical package R (version 2.13.0 [2011–04–13], The R
Foundation for statistical computing, Vienna, Austria).
Results
Baseline Profile
Table 1 summarizes the clinical and biological profile of the 716
participants. One hundred and ninety eight participants (27.7%)
had type 2 diabetes. Several expected differences according to
diabetes status were apparent in the study sample. For instance,
compared with nondiabetics, participants with diabetes were older
(59.9 vs. 51.3 years, p,0.0001), had higher body mass index (31.7
vs. 29.1 kg/m2, p,0.0001), higher waist-to-hip ratio (0.92 vs.
0.87, p,0.0001), higher systolic blood pressure (129 vs.
121 mmHg, p,0.0001) and included more individuals with
hypertension (65.1% vs. 34.0%, p,0.0001). Furthermore, they
were more likely to have higher urinary albumin/creatinine ratio
(median: 1.06 vs. 0.62, p,0.0001) and lower estimated glomerular
filtration rates based on either the MDRD, or CKD-EPI formulae
(both p#0.01), Table 1.
SNP Distribution
SNP rs5756152 was in linkage disequilibrium (LD) with both
rs4821480 (D9=0.682) and rs12107 (0. 169) in the overall cohort,
and in participants with diabetes (D9=0.797 and 0.171) and those
without diabetes (D9=0.636 and 0.168). SNP rs4821480 was in
weak LD with rs12107 in all the groups: participants without
diabetes (D9=0.147), participants with diabetes (D9=0.170),
overall cohort (D9=0.089). All the SNPs were in HWE (all
p.0.05) except rs4821480 in the overall cohort (p = 0.006) and in
participants with diabetes (p = 0.037). Therefore, rs4821480 was
removed from further analysis. The frequency distributions, both
genotype and allele, did not differ significantly according to
diabetes status. The A allele of rs575152, G allele of rs12107 and
G allele of rs4821480 were the most frequent overall and in
participants with and without diabetes (Table 2).
Association between SNPs within MYH9 and Renal Traits
The additive allelic effect of the SNPs on the traits differed
significantly between participants with and without diabetes. The
results are summarized Table 3. For each of the combinations of
trait and SNP showing a difference in the overall cohort, the effect
was significant only in those with type 2 diabetes where it was
further magnified in stratified analyses. For instance, in partici-
pants with diabetes, with each G allele of rs5756152, serum
creatinine decreased by 13% (95% confidence interval: 6.2–
19.7%), and eGFR (MDRD) or eGFR (CKD-EPI) increased by
11.08 (5.21–16.96) and 10.01 (4.85–15.33) ml/min respectively,
after adjustment for age, sex and urinary albumin excretion (loge).
Equivalents figures in nondiabetics were 2.2% (20.9 to 5.6%),
1.91 (21.32 to 5.15) and 1.83 (21.23 to 4.89), with significant
interactions in all according to diabetes status (all interaction
p$0.009). rs12107 was not associated with serum creatinine and
eGFR. Associations of the SNPs with urinary albumin excretion
tended to be significant in participants with diabetes (all p#0.10),
Table 1. Baseline characteristics overall and by diabetes status.
Characteristics No diabetes Diabetes P-value Overall
N 518 198 716
Gender, men n (%) 113 (21.8) 45 (22.7) 0.79 158 (22.1)
Mean age, years (SD) 51.3 (15.1) 59.9 (12.4) ,0.0001 53.6 (14.9)
Mean BMI, kg/m2 (SD) 29.1 (7.3) 31.7 (7.0) ,0.0001 29.8 (7.3)
Mean WHR (SD) 0.87 (0.08) 0.92 (0.08) ,0.0001 0.88 (0.08)
Mean SBP, mmHg (SD) 121 (18) 129 (20) ,0.0001 123 (19)
Mean DBP, mmHg (SD) 74 (12) 76 (13) 0.09 75 (12)
Hypertension, yes (%) 176 (34.0) 129 (65.1) ,0.0001 305 (42.3)
Mean HbA1c, % (SD) 5.7 (0.4) 7.7 (1.9) ,0.0001 6.2 (1.4)
Mean FBG, mmol/l (SD) 5.2 (0.7) 9.8 (4.1) ,0.0001 6.5 (3.0)
Mean 2-h glucose, mmol/l (SD) 6.5 (1.6) 13.3 (4.8) ,0.0001 7.7 (3.4)
Median urine creatinine, mmol/l (25th–75th percentiles) 8.1 (7.2–12.2) 6.6 (4.3–11.2) 0.02 7.8 (5.1–11.9)
Median urine Microalbumin, mg/l (25th–75th percentiles) 3.6 (3.0–9.6) 7.8 (3.0–25.6) ,0.0001 4.3 (3.0–11.8)
Median ACR, mg/mmol (25th–75th percentiles) 0.62 (0.37–1.21) 1.06 (0.59–3.21) ,0.0001 0.74 (0.41–1.54)
Normoalbuminuria (,3.4), n (%) 479 (92.5) 153 (77.3) ,0.0001 632 (88.3)
Microalbuminuria([3.4–33.9[), n (%) 38 (7.3) 31 (15.7) 69 (9.6)
Macroalbuminuria (.=33.9), n (%) 1 (0.2) 14 (7.1) 15 (2.1)
Albuminuria (.= 3.4), n (%) 39 (7.5) 45 (22.7) ,0.0001 84 (11.7)
Median serum creatinine,mmol/l (25th–75th percentiles) 81 (70–91) 85 (71–98) 0.04 81 (71–93)
Mean eGFR (MDRD), ml/min (SD) 87.6 (22.0) 82.1 (26.7) 0.01 86.1 (23.5)
eGFR (MDRD) ,60, n (%) 38 (7.3) 30 (15.2) 0.001 68 (9.5)
Mean eGRF (CKD-EPI), ml/min (SD) 92.1 (23.4) 83.0 (25.6) ,0.0001 89.6 (24.4)
eGFR (CKD-EPI) ,60, n (%) 36 (6.9) 31 (15.7) 0.0003 67 (9.4)
ACR, urinary albumin/creatinine ratio; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of
Diet in Renal Disease; SD, standard deviation.
doi:10.1371/journal.pone.0052529.t001
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but not in those without (all p$0.74), with also a trend toward
significant heterogeneity by diabetes status (all interaction
p#0.06), Table 3.
Association between SNPs within MYH9 and CKD stage
3–5, and Albuminuria
In logistic regression analyses, none of the SNPs, single or in the
presence of various combinations of quantitative and qualitative
traits achieved a significant association with CKD stage 3–5
(eGFR,60 ml/min) based on either MDRD or CKD-EPI
formulae (Table 4). However, effects were borderline with
rs5756152, with a suggestion that allele G could be associated
with about 34% to 48% lower risk of CKD, and consistently across
definitions of CKD (Table 4). We also found no significant
association between SNPs and proteinuria (ACR$3.4 mg/mmol),
irrespective of the level of adjustment for covariates (Table 5).
Association between SNPs within MYH9 and other Traits
The associations of participants’ quantitative traits known to be
related with CKD (including systolic blood pressure, fasting and 2-
hour glucose and HbA1c) and the three SNPs were assessed in age,
sex, ACR and diabetes adjusted regression models and after
stratification by diabetes status (Table 3). rs12107 was associated
with fasting-, 2-hour glucose and HbA1c in participants with
diabetes (all p#0.05) but only with 2-hour glucose in nondiabetics
(p = 0.03), with always significant interactions by diabetes status
(all interaction p#0.003). rs5756152 was also associated with
HbA1c in nondiabetics (both p#0.03), but not in people with
diabetes (both p$0.09), with however significant heterogeneity by
diabetes status (interaction p= 0.02). There was further suggestion
that associations of rs5756152 with fasting and 2-hour glucose,
although not significant, likely varied by diabetes status (both
interaction p#0.04). None of the SNPs was associated with systolic
blood pressure (Table 3).
Discussion
In this study we show that SNPs in the MYH9 gene are
associated with renal phenotypes in a mixed ancestry population of
South Africa with type 2 diabetes. This study contributes to
existing knowledge in several key ways. Firstly, it has shown that
polymorphisms within the MYH9 are associated with early
changes in kidney function and urinary albumin excretion in a
community based cohort as opposed to a patient population with
clinically overt chronic kidney disease. Secondly, it has demon-
strated that the associated MYH9 risk occurs at an early stage and
is likely more pronounced in subjects with type 2 diabetes unlike
previous studies which have shown a stronger association with
nondiabetic end-stage renal disease. Thirdly, it identified
rs5756152 to be the SNP with the strongest effect on renal
phenotypes. Finally, the MYH9 SNPs also showed an association
with CKD-related traits and those related to glucose control in
particular such as blood glucose and glycated hemoglobin.
In mixed ancestry populations such as the African Americans
and Hispanics, genome-wide studies have identified sequence
variants in the MYH9 gene, that demonstrated a strong
association with nondiabetic kidney disease [1,2,10,11]. The
mixed ancestry population of South Africa is also heterogeneous,
with predominantly San-Khoi, African, European origin and a
small proportion of Asian ancestry [21], but in contrast to these
reports the MYH9 polymorphisms in this population group were
strongly associated with renal traits in subjects with type 2
diabetes. Type 2 diabetes remains the strongest risk factor for renal
diseases, but MYH9 polymorphisms are only weakly associated
with diabetes related ESRD in both African and European
Americans [12,13]. Subjects with diabetes, particularly type 2
diabetes, in the presence or absence of diabetic nephropathy often
have diabetes-unrelated kidney diseases [22,23]. Our study is
different from the previous ones as it demonstrates an early
association between MYH9 polymorphisms and renal phenotypes
and describes the effect of MYH9 polymorphisms in a community
based cohort as opposed to clinically diagnosed ESRD. Our results
suggest that subjects with MYH9 risk alleles have an amplified risk
of CKD in the presence of type 2 diabetes, thus underscoring the
importance to aggressively monitor subjects with type 2 diabetes
for renal diseases.
Although the haplotypes, E-1, S-1 and L-1, confer all the excess
burden of diabetes-unrelated ESRD in African Americans and
Hispanics [1,2,10,11], three SNPs, rs12107, rs5756152 and
rs4821480, were found to be independently associated with
diabetes-unrelated ESRD. After adjusting for E-1 and L-1
haplotype, rs5756152 and rs12107 exhibited independent evi-
dence for association [11]. Similarly, Kao et al., showed significant
associations between MYH9 SNPs that included rs12107,
rs4821480 and rs5756152 and nondiabetic ESRD [2]. In our
study, the strongest association with changes in eGFR was
observed with rs5756152. Furthermore, rs5756152 G allele
showed borderline associations that may account for more than
30% lower risk for CKD stages 3–5. Although rs4821480 was
shown to be associated with CKD in individuals of European
ancestry from the Framingham Heart Study [24], we could not
confirm such an association. The lack of replication of these gene
polymorphisms has been reported in other populations including
those of African ancestry. For example, the L-1 SNPs were not
Table 2. Genotype distributions, minor allele frequencies,
and unadjusted p-values for comparing genotype
distributions according to diabetes status, additive allelic
effects between diabetes groups.
No diabetes Diabetes p-value Overall
N 518 198 716
rs5756152
A/A, n (%) 389 (75.1) 149 (75.2) 0.775 538 (75.1)
A/G, n (%) 120 (23.2) 44 (22.2) 164 (22.9)
G/G, n (%) 9 (1.7) 5 (2.5) 14 (1.9)
G, n (%) 129 (12.4) 49 (12.4) .0.999 178 (12.4)
HWE (p-value) .0.999 0.376 0.746
rs4821480
G/G, n (%) 202 (39.0) 80 (40.4) 0.710 282 (39.4)
G/T, n (%) 226 (43.6) 80 (40.4) 306 (42.7)
T/T, n (%) 90 (17.4) 38 (19.2) 128 (17.9)
T, n (%) 316 (30.5) 118 (29.8) 0.847 434 (30.3)
HWE (p-value) 0.053 0.037 0.006
rs12107
G/G, n (%) 286 (55.2) 112 (56.6) 0.930 398 (55.6)
G/A, n (%) 199 (38.4) 73 (36.9) 272 (38.0)
A/A, n (%) 33 (6.4) 13 (6.6) 46 (6.4)
A, n (%) 232 (22.4) 86 (21.7) 0.831 318 (22.2)
HWE (p-value) 0.908 0.850 .0.999
HWE, Hardy-Weindberg Equilibrium (HWE p-values are from exact tests).
doi:10.1371/journal.pone.0052529.t002
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Table 3. Generalized linear regression models showing the effects of genes on kidney functions and other continuous predictors.
Overall diabetes No diabetes p
interaction
Allele Phenotype Effects size (95%CI) p Effects size (95%CI) p Effects size (95%CI) p
rs5756152 G Serum creatinin (loge[mmol/l]) 25.1% (28.2 to 22.1) 0.001 213.0% (219.7
to 26.2)
0.0002 22.3% (25.6 to 0.9) 0.16 0.004
eGFR (MDRD) [ml/min] 4.71 (1.79 to 7.65) 0.002 11.08 (5.21 to 16.96) 0.0003 1.91 (21.32 to 5.15) 0.25 0.003
eGFR (CKD-EPI) [ml/min] 4.04 (1.37 to 6.70) 0.003 10.01 (4.85 to 15.33) 0.0002 1.83 (21.23 to 4.89) 0.24 0.009
Fasting blood glucose (mmol/l) 0.37 (0.04 to 0.71) 0.030 0.91 (20.25 to 2.07) 0.13 0.14 (0.01 to 0.27) 0.03 0.03
2-hour blood glucose (mmol/l) 0.04 (20.33 to 0.41) 0.82 0.86 (21.15 to 2.87) 0.81 20.11 (20.38 to 0.15) 0.41 0.04
HbA1c (%) 0.04 (20.12 to 0.20) 0.63 0.29 (20.27 to 0.85) 0.31 20.08 (20.15 to 20.01) 0.03 0.02
Albumin/creatinine ratio (mg/mmol) 10.8% (26.4 to 28.0) 0.22 43.6% (0.1 to 87.1) 0.05 21.6% (218.9 to 15.6) 0.85 0.02
Systolic blood pressure (mmHg) 21.35 (23.99 to 1.29) 0.32 20.63 (26.27 to 5.02) 0.83 21.76 (24.73 to 1.22) 0.25 0.65
rs12107 A Serum creatinin (loge[mmol/l]) 0.05% (22.4 to 2.5) 0.97 20.2% (25.7 to 5.2%) 0.93 0.4% (22.2 to 2.9) 0.78 0.60
eGFR (MDRD) [ml/min] 0.06 (22.26 to 2.37) 0.96 20.17 (25.05 to 4.71) 0.94 20.07 (22.61 to 2.46) 0.95 0.84
eGFR (CKD-EPI) [ml/min] 0.37 (21.73 to 2.48) 0.73 0.68 (23.55 to 4.90) 0.75 0.13 (22.27 to 2.54) 0.91 0.62
Fasting blood glucose (mmol/l) 20.31 (20.57 to 20.04) 0.022 20.90 (21.81
to 20.004)
0.05 20.07 (20.17 to 0.03) 0.17 0.003
2-hour blood glucose (mmol/l) 20.51 (20.79 to 0.22) 0.0005 21.88 (23.33
to 20.44)
0.01 20.23 (20.44 to 20.02) 0.03 ,0.0001
HbA1c (%) 20.13 (20.25
to 20.001)
0.05 20.54 (20.97 to 20.11) 0.01 0.04 (20.02 to 0.09) 0.18 ,0.0001
Albumin/creatinine ratio (mg/mmol) 27.3% (220.8 to 6.2) 0.29 228.8% (262.8 to 5.2) 0.10 1.0% (212.6 to 14.5) 0.90 0.054
Systolic blood pressure (mmHg) 0.22 (21.85 to 2.29) 0.83 0.54 (23.86 to 4.93) 0.81 0.13 (22.20 to 2.47) 0.91 0.88
Models are adjusted for age, sex, diabetes and urinary albumin/creatinine ratio.
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
doi:10.1371/journal.pone.0052529.t003
Table 4. Odd ration and 95% confidence intervals from logistic regression for the prediction of CKD stage 3–5.
Allele Covariates MDRD p CKD-EPI p
rs5756152 G None 0.66 (0.36–1.15) 0.17 0.61 (0.32–1.09) 0.12
Age, sex 0.62 (0.32–1.14) 0.14 0.57 (0.27–1.08) 0.10
Age, sex, diabetes 0.62 (0.31–1.13) 0.14 0.56 (0.27–1.07) 0.09
Age, sex, ACR 0.56 (0.27–1.05) 0.09 0.52 (0.24–1.02) 0.07
Age, sex, ACR, diabetes 0.56 (0.27–1.05) 0.09 0.52 (0.25–1.02) 0.07
Age, sex, ACR, diabetes, diabetes*ACR 0.56 (0.27–1.05) 0.08 0.53 (0.25–1.04) 0.08
Age, sex, ACR, diabetes, hypertension 0.57 (0.28–1.07) 0.10 0.54 (0.25–1.05) 0.09
Age, sex, ACR, diabetes, HbA1c 0.55 (0.27–1.04) 0.08 0.52 (0.24–1.01) 0.07
rs12107 0.57 (0.29–1.03) 0.08 0.53 (0.26–0.97) 0.05
rs12107 A None 1.15 (0.77–1.70) 0.48 1.13 (0.75–1.68) 0.54
Age, sex 1.23 (0.77–1.92) 0.38 1.23 (0.75–1.98) 0.40
Age, sex, diabetes 1.24 (0.78–1.96) 0.36 1.24 (0.76–2.01) 0.38
Age, sex, ACR 1.33 (0.83–2.08) 0.22 1.31 (0.80–2.12) 0.27
Age, sex, ACR, diabetes 1.33 (0.84–2.08) 0.22 1.31 (0.80–2.12) 0.27
Age, sex, ACR, diabetes, diabetes*ACR 1.33 (0.84–2.08) 0.22 1.32 (0.80–2.13) 0.27
Age, sex, ACR, diabetes, hypertension 1.34 (0.84–1.12) 0.21 1.32 (0.80–2.15) 0.27
Age, sex, ACR, diabetes, HbA1c 1.31 (0.83–2.06) 0.24 1.30 (0.79–2.10) 0.29
rs5756152 1.21 (0.81–1.78) 0.35 1.19 (0.79–1.76) 0.39
ACR, urinary albumin/creatinine ratio; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of
Diet in Renal Disease.
doi:10.1371/journal.pone.0052529.t004
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significantly associated with non-diabetic ESRD in Hispanic
Americans with varying degrees of Native American, African
and European ancestries [10]. Similarly, in an HIV-infected
African Ethiopian population the presence of a comparable
frequency with African Americans of the E-1 haplotype was found
in the absence of clinically apparent HIVAN [25].
Despite the identification of disease susceptible MYH9 SNPs,
the disease causal mechanism remains largely unknown. The non-
muscle myosin protein is abundantly expressed in the kidney,
platelets and liver and in smaller amounts in the thymus, spleen,
intestine and cochlea [3,26,27]. Within the kidney, it is expressed
in the podocytes which are highly specialized cell, with the ability
to ultrafilter blood and support glomerular capillary pressures
[28,29]. Although differentiation of podocytes has been associated
with the up-regulation of actin-myosin molecules, MYH9 and
MYH10 were not amongst those genes [29]. Herein, we did not
find an association with blood pressure; instead we found that
MYH9 polymorphisms affected blood glucose levels and glycated
hemoglobin. The role of MYH9 in diabetes susceptibility has
previously been proposed. Freedman et al [11] proposed that the
association between MYH9 and diabetes associated ESRD could
have resulted from MYH9 causing susceptibility to type 2 diabetes.
Later the authors showed MYH9 polymorphisms specifically the
E-1 haplotype to modulate the genetic effect of FERM domain-
containing protein 3 (FRMD3) for diabetes susceptibility [30].
However, FRMD3 alleles were not associated with increased risk
of type 2 diabetes in subjects carrying MYH9 E-1 risk alleles.
Similarly, genome-wide linkage analysis has revealed genetic
variants on chromosome 22, near the MYH9 and APOL1 to be
linked to the pathogenesis of diabetes [31]. Taken together with
the diabetes-renal disease risk, it is likely that MYH9 exerts this
effect through disregulation of blood glucose metabolism, as such
future work is warranted.
Our study also has important public health implications. This
population is at an increased risk for CKD which is driven by a
high prevalence of diabetes. An epidemic of diabetes in South
Africa is magnified by the HIV/AIDS epidemic where the largest
HIV infected population in the world resides [32,33,34,35,36].
Individuals with both HIV and diabetes are reported to be at
significantly increased risk of progressive CKD compared with
patients with only one commodity [37]. Furthermore, HIV
associated nephropathy is strongly linked to MYH9 polymorphism
in African Americans [38]. The aggregation of multiple risk factors
on the development of CKD is of concern in this population.
Therefore, our study and those previously reported emphasize the
need to conduct prospective studies that can elucidate the value of
genetic screening for CKD. Hopefully, such screening would lead
to early differential diagnosis and treatment strategies that would
delay CKD progression.
The limitations of this study include the design which is cross-
sectional. The phenotypes were based on a single measurement.
Further, the lack of data mapping the admixture ancestry markers
limited our choice of SNPs. Although rs5756152 showed the
strongest association with renal phenotypes, it is likely that other
SNPs within the MYH9 may prove otherwise. Although, the
MYH9 risk alleles are highly prevalent in populations with an
African ancestry including the indigenous San and Bantu-South
Africans [39] this is the first report confirming an association
between MYH9 SNPs and renal phenotypes in a South African
population.
In conclusion, rs5756152 is associated with early kidney
function derangements in South African mixed ancestry subjects
with type 2 diabetes whilst rs12107 is associated with glucose
control. Our findings and other studies suggest that MYH9 may
have a broader genetic risk effect on different types of kidney
diseases. Further studies are needed to replicate our findings, and
we recommend that these should include patients with diagnosed
ESRD.
Acknowledgments
We thank the Bellville South community for participating in the study.
All authors read and approved the manuscript as written. A.P.K is the
guarantor of this work and, as such, had full access to all data in the study
and takes responsibility for the integrity of the data and the accuracy of the
data analysis.
Author Contributions
Conceived and designed the experiments: TEM RTE. Performed the
experiments: TEM KMYYYMSH. Analyzed the data: APK TEM. Wrote
the paper: TEM YYY APK KM MSH MM RTE.
References
1. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, et al. (2008)
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature
genetics 40: 1175–1184.
2. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, et al. (2008)
MYH9 is associated with nondiabetic end-stage renal disease in African
Americans. Nature genetics 40: 1185–1192.
3. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, et al. (2002)
Expression of the nonmuscle myosin heavy chain IIA in the human kidney and
screening for MYH9 mutations in Epstein and Fechtner syndromes. Journal of
the American Society of Nephrology : JASN 13: 65–74.
Table 5. Odd ratio and 95% confidence intervals from logistic regression for the prediction of proteinuria.
Covariates rs5756152 G P rs12107 A p
None 1.27 (0.80–1.95) 0.28 0.87 (0.59–1.26) 0.48
Age, sex 1.27 (0.80–1.95) 0.28 0.89 (0.60–1.30) 0.55
Age, sex, diabetes 1.28 (0.80–1.99) 0.28 0.89 (0.59–1.30) 0.56
Age, sex, CKD (MDRD), diabetes 1.30 (0.82–2.03) 0.25 0.89 (0.59–1.30) 0.55
Age, sex, CKD (CKD-EPI), diabetes 1.29 (0.80–2.01) 0.27 0.89 (0.59–1.30) 0.56
Age, sex, CKD (MDRD), diabetes, hypertension 1.33 (0.83–2.08) 0.22 0.91 (0.60–1.33) 0.63
rs12107 1.25 (0.77–1.98) 0.36 0.86 (0.58–1.25) 0.44
doi:10.1371/journal.pone.0052529.t005
MYH9 Gene and Renal Traits in Diabetes
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e52529
4. Kopp JB (2010) Glomerular pathology in autosomal dominant MYH9 spectrum
disorders: what are the clues telling us about disease mechanism? Kidney
international 78: 130–133.
5. Kitiyakara C, Eggers P, Kopp JB (2004) Twenty-one-year trend in ESRD due to
focal segmental glomerulosclerosis in the United States. American journal of
kidney diseases : the official journal of the National Kidney Foundation 44: 815–
825.
6. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, et al. (1989) Disparities in
incidence of diabetic end-stage renal disease according to race and type of
diabetes. The New England journal of medicine 321: 1074–1079.
7. Toto RD (2004) Proteinuria and hypertensive nephrosclerosis in African
Americans. Kidney international Supplement: S102–104.
8. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, et al.
(2007) A multiethnic, multicenter cohort of patients with systemic lupus
erythematosus (SLE) as a model for the study of ethnic disparities in SLE.
Arthritis and rheumatism 57: 576–584.
9. Kopp JB, Winkler C (2003) HIV-associated nephropathy in African Americans.
Kidney international Supplement: S43–49.
10. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, et al. (2010) African
ancestry allelic variation at the MYH9 gene contributes to increased
susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans.
Human molecular genetics 19: 1816–1827.
11. Freedman BI, Kopp JB, Winkler CA, Nelson GW, Rao DC, et al. (2009)
Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are
associated with albuminuria in hypertensive African Americans: the HyperGEN
study. American journal of nephrology 29: 626–632.
12. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, et al. (2009) Non-
muscle myosin heavy chain 9 gene MYH9 associations in African Americans
with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrology,
dialysis, transplantation : official publication of the European Dialysis and
Transplant Association - European Renal Association 24: 3366–3371.
13. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, et al. (2012)
Polymorphisms in MYH9 are associated with diabetic nephropathy in European
Americans. Nephrology, dialysis, transplantation : official publication of the
European Dialysis and Transplant Association - European Renal Association 27:
1505–1511.
14. Zemlin AE, Matsha TE, Hassan MS, Erasmus RT (2011) HbA1c of 6.5% to
diagnose diabetes mellitus – does it work for us? – the Bellville South Africa
study. PloS one 6: e22558.
15. Matsha TE, Hassan MS, Kidd M, Erasmus RT (2012) The 30-year
cardiovascular risk profile of South Africans with diagnosed diabetes,
undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South
Africa pilot study. Cardiovascular journal of Africa 23: 5–11.
16. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, et al. (1999) 1999
World Health Organization-International Society of Hypertension Guidelines
for the management of hypertension. Guidelines sub-committee of the World
Health Organization. Clinical and experimental hypertension 21: 1009–1060.
17. WHO Consultation (1999) definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of diabetes
mellitus. Geneva: World Health Organisation.
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using
standardized serum creatinine values in the modification of diet in renal disease
study equation for estimating glomerular filtration rate. Ann Intern Med 145:
247–254.
19. Levey AS, Green T, Kusek JW, Beck GJ (2000) A simplified equation to predict
glomerular filtration rate from serum creatinin. J Am Soc Nephrol 11: 155A.
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A
new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–
612.
21. de Wit E, Delport W, Rugamika CE, Meintjes A, Moller M, et al. (2010)
Genome-wide analysis of the structure of the South African Coloured Population
in the Western Cape. Human genetics 128: 145–153.
22. Bostrom MA, Freedman BI (2010) The spectrum of MYH9-associated
nephropathy. Clinical journal of the American Society of Nephrology : CJASN
5: 1107–1113.
23. Cordonnier D (1996) Glomerular involvement in type II diabetes - is it all
diabetic glomerulosclerosis? Nephrology, dialysis, transplantation : official
publication of the European Dialysis and Transplant Association - European
Renal Association 11: 936–938.
24. O’Seaghdha CM, Parekh RS, Hwang SJ, Li M, Kottgen A, et al. (2011) The
MYH9/APOL1 region and chronic kidney disease in European-Americans.
Human molecular genetics 20: 2450–2456.
25. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, et al. (2010) Missense
mutations in the APOL1 gene are highly associated with end stage kidney
disease risk previously attributed to the MYH9 gene. Human genetics 128: 345–
350.
26. Sellers JR (2000) Myosins: a diverse superfamily. Biochimica et biophysica acta
1496: 3–22.
27. Herrema H, Czajkowska D, Theard D, van der Wouden JM, Kalicharan D, et
al. (2006) Rho kinase, myosin-II, and p42/44 MAPK control extracellular
matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells.
Molecular biology of the cell 17: 3291–3303.
28. Perry J, Tam S, Zheng K, Sado Y, Dobson H, et al. (2006) Type IV collagen
induces podocytic features in bone marrow stromal stem cells in vitro. Journal of
the American Society of Nephrology : JASN 17: 66–76.
29. Saleem MA, Zavadil J, Bailly M, McGee K, Witherden IR, et al. (2008) The
molecular and functional phenotype of glomerular podocytes reveals key features
of contractile smooth muscle cells. American journal of physiology Renal
physiology 295: F959–970.
30. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, et al. (2011)
Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association
with Diabetic ESRD in African Americans. PLoS genetics 7: e1002150.
31. Igo RP Jr, Iyengar SK, Nicholas SB, Goddard KA, Langefeld CD, et al. (2011)
Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND
study. American journal of nephrology 33: 381–389.
32. Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST (2010) Diabetes in
sub-Saharan Africa. Lancet 375: 2254–2266.
33. Levitt NS, Bradshaw D (2006) The impact of HIV/AIDS on Type 2 diabetes
prevalence and diabetes healthcare needs in South Africa: projections for 2010.
Diabetic medicine : a journal of the British Diabetic Association 23: 103–104.
34. Levitt NS (2008) Diabetes in Africa: epidemiology, management and healthcare
challenges. Heart 94: 1376–1382.
35. Hall V, Thomsen RW, Henriksen O, Lohse N (2011) Diabetes in Sub Saharan
Africa 1999–2011: epidemiology and public health implications. A systematic
review. BMC public health 11: 564.
36. Young F, Critchley JA, Johnstone LK, Unwin NC (2009) A review of co-
morbidity between infectious and chronic disease in Sub Saharan Africa: TB
and diabetes mellitus, HIV and metabolic syndrome, and the impact of
globalization. Globalization and health 5: 9.
37. Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, et al. (2012)
Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in
HIV-Infected Adults: Data From the Veterans Aging Cohort Study. Journal of
acquired immune deficiency syndromes 60: 393–399.
38. Winkler C (2010) Is there a genetic basis for health disparities in human
immunodeficiency virus disease? The Mount Sinai journal of medicine, New
York 77: 149–159.
39. Oleksyk TK, Nelson GW, An P, Kopp JB, Winkler CA (2010) Worldwide
distribution of the MYH9 kidney disease susceptibility alleles and haplotypes:
evidence of historical selection in Africa. PloS one 5: e11474.
MYH9 Gene and Renal Traits in Diabetes
PLOS ONE | www.plosone.org 7 December 2012 | Volume 7 | Issue 12 | e52529
